durvalumab,oleclumab
astrazeneca
['increase,(-increased)', 'synergy', 'bcsm', 'tnbc', 'durva', 'oleclumab']
oleclumab, durvalumab and chemotherapy did not increase clinical benefit rate in patients with advanced #tnbc vs durvalumab and chemotherapy alone as a first-line treatment, according to the phase 2 synergy trial. #esmo2022 #bcsm | 
Oncology news and insights from leading researchers and cancer centers.